The effect of Bosentan in the treatment of pulmonary hypertension in patients with COVID-19

Phase 2

Recruiting

• Conditions: U07.2; U07.1; Condition 1: COVID-19. Condition 2: COVID-19.; COVID-19, virus not identified; COVID-19, virus identified

• Registration Number: IRCT20210710051831N1
• Lead Sponsor: Qazvin University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 30 August 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Patients with COVID-19 referred to Boali Sina hospital, Qazvin during 1400
patients with COVID-19 pneumonia and pulmonary hypertension
Willingness to participate in a research project
Signing the informed consent form

Exclusion Criteria

Age range under 14 years
Pregnant women
History of pulmonary hypertension
Severe obstructive pulmonary disease

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pulmonary artery systolic pressure. Timepoint: Before and 10 days after the intervention. Method of measurement: Echocardiography.